As flu test positivity crept upward, emergency department visits increased slightly among children and adolescents.
The drug was 88% effective against the need for medical attention among those in their second respiratory virus season.
RSV is the leading cause of hospitalization for US infants, but it also causes severe and serious illnesses in adults.
As of last year, RSV vaccination with Abrysvo has been recommended for pregnant women in the United States from 32 to 36 weeks gestation.
Meanwhile, COVID activity remained low amid a shift in variant proportions and RSV levels rose in 3 US regions.
About 2% of antibiotic prescriptions over the study period were connected to RSV diagnoses, especially in seniors and infants.
PAHO says it will provide countries in the Americas with affordable access to respiratory syncytial virus vaccine.
Nirsevimab and Avrexy were shown to be 83% and 67% effective at preventing hospitalization, respectively.
Though the KP.3.1.1 variant is still dominant, levels of the newer XEC variant continue to rise.
One clade of eight RSV-B genomes had a mutation tied to resistance to the monoclonal antibody nirsevimab.
